Immunotherapy for cancer: synthetic carbohydrate-based vaccines

Aberrant glycosylation of glycoproteins and glycolipids of cancer cells, which correlates with poor survival rates, is being exploited for the development of immunotherapies for cancer. In particular, advances in the knowledge of cooperation between the innate and adaptive system combined with the i...

Full description

Saved in:
Bibliographic Details
Published in:Chemical communications (Cambridge, England) England), 2009-01 (36), p.5335-5349
Main Authors: Buskas, Therese, Thompson, Pamela, Boons, Geert-Jan
Format: Article
Language:English
Subjects:
Animals
Antibodies - blood
Antibodies - immunology
Antigens, Tumor-Associated, Carbohydrate - chemistry
Antigens, Tumor-Associated, Carbohydrate - immunology
cancer vaccines
Cancer Vaccines - chemical synthesis
Cancer Vaccines - chemistry
Cancer Vaccines - immunology
Carbohydrate Sequence
chemical communication
chemical compounds
glycolipids
glycopeptides
glycoproteins
glycosylation
Humans
immune response
immunotherapy
Molecular Sequence Data
neoplasm cells
neoplasms
Neoplasms - chemistry
Neoplasms - immunology
Neoplasms - pathology
Neoplasms - therapy
oligosaccharides
survival rate
vaccine development
Vaccines, Subunit - chemical synthesis
Vaccines, Subunit - chemistry
Vaccines, Subunit - immunology
Vaccines, Synthetic - chemistry
Vaccines, Synthetic - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aberrant glycosylation of glycoproteins and glycolipids of cancer cells, which correlates with poor survival rates, is being exploited for the development of immunotherapies for cancer. In particular, advances in the knowledge of cooperation between the innate and adaptive system combined with the implementation of efficient synthetic methods for assembly of oligosaccharides and glycopeptides is providing avenues for the rationale design of vaccine candidates. In this respect, fully synthetic vaccine candidates show great promise because they incorporate only those elements requires for relevant immune responses, and hence do not suffer from immune suppression observed with classical carbohydrate-protein conjugate vaccines. Such vaccines are chemically well-defined and it is to be expected that they can be produced in a reproducible fashion. In this feature article, recent advances in the development of fully synthetic sub-unit carbohydrate-based cancer vaccines will be discussed.
ISSN:1359-7345
1364-548X
1364-548X
DOI:10.1039/b908664c